Management of locally advanced prostate cancer: appraisal of current paradigms and future directions

in Endocrine-Related Cancer
View More View Less
  • 1 M Sandoval, Radiation Oncology, Moffitt Cancer Center, Tampa, 33612-9416, United States
  • 2 A Dohm, Radiation Oncology, Moffitt Cancer Center, Tampa, United States
  • 3 K Yamoah, Radiation Oncology, Moffitt Cancer Center, Tampa, United States

Correspondence: Kosj Yamoah, Email: Kosj.Yamoah@moffitt.org
Restricted access

The current standard for the management of locally advanced and early-stage metastatic prostate cancer relies on a backbone of androgen deprivation therapy (ADT) combined with radiotherapy (RT), a regimen that at a glance appears relatively straightforward. The emergence of newer diagnostic, genomic and imaging modalities have allowed for better disease risk-stratification and opened avenues for the development of more patient-centered treatment strategies. This review aims to highlight the central role of RT as part of a multi-modal approach, and discuss established and emerging data for the management of locally advanced disease, biochemical recurrence, and oligometastatic disease, as well as the use of immunotherapies and radio-isotopes. This review will also briefly discuss ongoing clinical trials that provide new insights into the paradigm shift in the management of locally advanced prostate cancer.

 

Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 160 160 160
Full Text Views 7 7 7
PDF Downloads 8 8 8